|0.7600||+0.0199||+2.69%||Vol 4.47M||1Y Perf -94.63%|
|Oct 4th, 2023 15:23 DELAYED|
|0.06 7.92%||- -|
|Target Price||17.60||Analyst Rating||Moderate Sell 3.60|
|Potential %||2.22K||Finscreener Ranking||★ 41.14|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||☆ 32.21|
|Insiders Value % 3/6/12 mo.||-/-/-62||Growth Ranking||★+ 41.77|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-62||Income Ranking||— -|
|Price Range Ratio 52W %||0.24||Earnings Rating||Sell|
|Market Cap||74.64M||Earnings Date||6th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th Nov 2023|
|Estimated EPS Next Report||-0.68|
|EPS Growth Next 5 Years %||33.80|
|Avg. Weekly Volume||6.04M|
|Avg. Monthly Volume||6.47M|
|Avg. Quarterly Volume||4.40M|
FibroGen Inc (NASDAQ: FGEN) stock closed at 0.7401 per share at the end of the most recent trading day (a -8.63% change compared to the prior day closing price) with a volume of 5.75M shares and market capitalization of 74.64M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 531 people. FibroGen Inc CEO is Enrique A. Conterno.
The one-year performance of FibroGen Inc stock is -94.63%, while year-to-date (YTD) performance is -95.38%. FGEN stock has a five-year performance of -98.72%. Its 52-week range is between 0.701 and 25.69, which gives FGEN stock a 52-week price range ratio of 0.24%
FibroGen Inc currently has a PE ratio of -5.10, a price-to-book (PB) ratio of 70.68, a price-to-sale (PS) ratio of 17.58, a price to cashflow ratio of 12.50, a PEG ratio of -0.15, a ROA of -44.18%, a ROC of -132.33% and a ROE of -172.16%. The company’s profit margin is -83.64%, its EBITDA margin is -287.20%, and its revenue ttm is $106.37 Million , which makes it $1.13 revenue per share.
Of the last four earnings reports from FibroGen Inc, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.68 for the next earnings report. FibroGen Inc’s next earnings report date is 06th Nov 2023.
The consensus rating of Wall Street analysts for FibroGen Inc is Moderate Sell (3.6), with a target price of $17.6, which is +2 216.70% compared to the current price. The earnings rating for FibroGen Inc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
FibroGen Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
FibroGen Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 22.26, ATR14 : 0.12, CCI20 : -129.00, Chaikin Money Flow : -0.11, MACD : -0.19, Money Flow Index : 28.34, ROC : -14.25, RSI : 31.17, STOCH (14,3) : 13.11, STOCH RSI : 0.00, UO : 42.19, Williams %R : -86.89), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of FibroGen Inc in the last 12-months were: Aoife Brennan (Sold 4 733 shares of value $81 367 ), Blaug Suzanne (Sold 17 040 shares of value $293 142 ), Brennan Aoife (Sold 4 733 shares of value $81 367 ), Christine Chung (Sold 9 185 shares of value $164 760 ), Chung Christine (Sold 51 161 shares of value $938 797 ), Conterno Enrique (Sold 88 054 shares of value $1 772 606 ), Conterno Enrique A (Sold 8 897 shares of value $151 583 ), Cravatt Benjamin (Sold 7 888 shares of value $135 434 ), EDWARDS JEFFREY L (Sold 7 889 shares of value $135 622 ), Eisner Mark (Sold 34 136 shares of value $669 664 ), Enrique A. Conterno (Sold 21 027 shares of value $424 308 ), Graham Juan (Sold 11 231 shares of value $218 033 ), Henderson Jeffrey William (Sold 7 000 shares of value $122 185 ), Ho Maykin (Sold 8 520 shares of value $148 591 ), Jeffrey W. Henderson (Sold 2 000 shares of value $2 060 ), Juan Graham (Sold 7 929 shares of value $117 536 ), Mark Eisner (Sold 10 369 shares of value $198 433 ), Schoeneck James (Sold 7 100 shares of value $128 013 ), Schoeneck James A (Sold 7 100 shares of value $127 987 ), Thane Wettig (Sold 734 shares of value $11 597 ), Wettig Thane (Sold 19 146 shares of value $377 396 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.